Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

NCT01558739 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post Polycythaemia Myelofibrosis (PPV MF)
Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Interventions

DRUG: INC424

Sponsor

Novartis Pharmaceuticals